Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 148

1.

The topology of Vitronectin: a complementary feature for neuroblastoma risk classification based on computer-aided detection.

Vicente-Munuera P, Burgos-Panadero R, Noguera I, Navarro S, Noguera R, Escudero LM.

Int J Cancer. 2019 Jun 7. doi: 10.1002/ijc.32495. [Epub ahead of print]

PMID:
31173338
2.

Vitronectin as a molecular player of the tumor microenvironment in neuroblastoma.

Burgos-Panadero R, Noguera I, Cañete A, Navarro S, Noguera R.

BMC Cancer. 2019 May 22;19(1):479. doi: 10.1186/s12885-019-5693-2.

3.

A Mechanistic Model for the Extraction of Phenolics from Grapes During Red Wine Fermentation.

Miller KV, Noguera R, Beaver J, Medina-Plaza C, Oberholster A, Block DE.

Molecules. 2019 Apr 2;24(7). pii: E1275. doi: 10.3390/molecules24071275.

4.

Extra-Adrenal Adult Neuroblastoma With Aberrant Germ Cell Marker Expression: Maturation After Chemotherapy as an Important Clue to a Challenging Diagnosis.

Martinez-Ciarpaglini C, Machado I, Yoshida A, Nieto G, Berbegall AP, Blanquer-Maceíras MT, Noguera R, Ferrández A, Navarro S.

Int J Surg Pathol. 2019 Mar 24:1066896919835945. doi: 10.1177/1066896919835945. [Epub ahead of print]

PMID:
30907195
5.

[An integral view of cancer (I). The study, classification and reprogramming of the tumoral microclimate].

Noguera R, Burgos-Panadero R, Gamero-Sandemetrio E, de la Cruz-Merino L, Álvaro Naranjo T.

Rev Esp Patol. 2019 Apr - Jun;52(2):92-102. doi: 10.1016/j.patol.2018.11.003. Epub 2019 Feb 10. Review. Spanish.

PMID:
30902384
6.

Therapeutic opportunities in neuroblastoma using nanotechnology.

Rodriguez-Nogales C, Noguera R, Patrick C, Blanco-Prieto MJJ.

J Pharmacol Exp Ther. 2019 Jan 11. pii: jpet.118.255067. doi: 10.1124/jpet.118.255067. [Epub ahead of print]

7.

High Oct4 expression: implications in the pathogenesis of neuroblastic tumours.

Monferrer E, Burgos-Panadero R, Blanquer-Maceiras M, Cañete A, Navarro S, Noguera R.

BMC Cancer. 2019 Jan 3;19(1):1. doi: 10.1186/s12885-018-5219-3.

8.

Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients.

Zeka F, Decock A, Van Goethem A, Vanderheyden K, Demuynck F, Lammens T, Helsmoortel HH, Vermeulen J, Noguera R, Berbegall AP, Combaret V, Schleiermacher G, Laureys G, Schramm A, Schulte JH, Rahmann S, Bienertová-Vašků J, Mazánek P, Jeison M, Ash S, Hogarty MD, Moreno-Smith M, Barbieri E, Shohet J, Berthold F, Van Maerken T, Speleman F, Fischer M, De Preter K, Mestdagh P, Vandesompele J.

JCI Insight. 2018 Dec 6;3(23). pii: 97021. doi: 10.1172/jci.insight.97021.

9.

Patient-Derived Xenograft Models Reveal Intratumor Heterogeneity and Temporal Stability in Neuroblastoma.

Braekeveldt N, von Stedingk K, Fransson S, Martinez-Monleon A, Lindgren D, Axelson H, Levander F, Willforss J, Hansson K, Øra I, Backman T, Börjesson A, Beckman S, Esfandyari J, Berbegall AP, Noguera R, Karlsson J, Koster J, Martinsson T, Gisselsson D, Påhlman S, Bexell D.

Cancer Res. 2018 Oct 15;78(20):5958-5969. doi: 10.1158/0008-5472.CAN-18-0527. Epub 2018 Aug 28.

PMID:
30154149
10.

Lymph microvascularization as a prognostic indicator in neuroblastoma.

Tadeo I, Gamero-Sandemetrio E, Berbegall AP, Gironella M, Ritort F, Cañete A, Bueno G, Navarro S, Noguera R.

Oncotarget. 2018 May 25;9(40):26157-26170. doi: 10.18632/oncotarget.25457. eCollection 2018 May 25.

11.

9-ING-41, a small-molecule glycogen synthase kinase-3 inhibitor, is active in neuroblastoma.

Ugolkov AV, Bondarenko GI, Dubrovskyi O, Berbegall AP, Navarro S, Noguera R, O'Halloran TV, Hendrix MJ, Giles FJ, Mazar AP.

Anticancer Drugs. 2018 Sep;29(8):717-724. doi: 10.1097/CAD.0000000000000652.

PMID:
29846250
12.

Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study.

Berbegall AP, Bogen D, Pötschger U, Beiske K, Bown N, Combaret V, Defferrari R, Jeison M, Mazzocco K, Varesio L, Vicha A, Ash S, Castel V, Coze C, Ladenstein R, Owens C, Papadakis V, Ruud E, Amann G, Sementa AR, Navarro S, Ambros PF, Noguera R, Ambros IM.

Br J Cancer. 2018 May;118(11):1502-1512. doi: 10.1038/s41416-018-0098-6. Epub 2018 May 14.

13.

Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients.

Depuydt P, Boeva V, Hocking TD, Cannoodt R, Ambros IM, Ambros PF, Asgharzadeh S, Attiyeh EF, Combaret V, Defferrari R, Fischer M, Hero B, Hogarty MD, Irwin MS, Koster J, Kreissman S, Ladenstein R, Lapouble E, Laureys G, London WB, Mazzocco K, Nakagawara A, Noguera R, Ohira M, Park JR, Pötschger U, Theissen J, Tonini GP, Valteau-Couanet D, Varesio L, Versteeg R, Speleman F, Maris JM, Schleiermacher G, De Preter K.

J Natl Cancer Inst. 2018 Oct 1;110(10):1084-1093. doi: 10.1093/jnci/djy022.

14.

1p36 deletion results in a decrease in glycosaminoglycans which is associated with aggressiveness in neuroblastic tumors.

Tadeo I, Gamero-Sandemetrio E, Berbegall AP, Navarro S, Cañete A, Noguera R.

Histol Histopathol. 2018 May;33(5):487-495. doi: 10.14670/HH-11-947. Epub 2017 Nov 23.

PMID:
29168879
15.

Congenital undifferentiated sarcoma associated to BCOR-CCNB3 gene fusion.

Alfaro-Cervello C, Andrade-Gamarra V, Nieto G, Navarro L, Martín-Vañó S, García de la Torre JP, Bengoa Caamaño M, García Mauriño ML, Noguera R, Navarro S.

Pathol Res Pract. 2017 Nov;213(11):1435-1439. doi: 10.1016/j.prp.2017.07.012. Epub 2017 Jul 14.

PMID:
28756981
16.

A stiff extracellular matrix is associated with malignancy in peripheral neuroblastic tumors.

Tadeo I, Berbegall AP, Navarro S, Castel V, Noguera R.

Pediatr Blood Cancer. 2017 Sep;64(9). doi: 10.1002/pbc.26449. Epub 2017 Jan 25.

PMID:
28121069
17.

Stage 4S neuroblastoma tumors show a characteristic DNA methylation portrait.

Decock A, Ongenaert M, De Wilde B, Brichard B, Noguera R, Speleman F, Vandesompele J.

Epigenetics. 2016 Oct 2;11(10):761-771. doi: 10.1080/15592294.2016.1226739.

18.

Extracellular matrix composition defines an ultra-high-risk group of neuroblastoma within the high-risk patient cohort.

Tadeo I, Berbegall AP, Castel V, García-Miguel P, Callaghan R, Påhlman S, Navarro S, Noguera R.

Br J Cancer. 2016 Aug 9;115(4):480-9. doi: 10.1038/bjc.2016.210. Epub 2016 Jul 14.

19.

Diagnostic implications of intrapatient genetic tumor heterogeneity.

Berbegall AP, Navarro S, Noguera R.

Mol Cell Oncol. 2015 Sep 11;3(2):e1079671. doi: 10.1080/23723556.2015.1079671. eCollection 2016 Mar.

20.

Neuroblastoma patient-derived orthotopic xenografts reflect the microenvironmental hallmarks of aggressive patient tumours.

Braekeveldt N, Wigerup C, Tadeo I, Beckman S, Sandén C, Jönsson J, Erjefält JS, Berbegall AP, Börjesson A, Backman T, Øra I, Navarro S, Noguera R, Gisselsson D, Påhlman S, Bexell D.

Cancer Lett. 2016 Jun 1;375(2):384-389. doi: 10.1016/j.canlet.2016.02.046. Epub 2016 Mar 18.

21.

BRG1/SMARCA4 is essential for neuroblastoma cell viability through modulation of cell death and survival pathways.

Jubierre L, Soriano A, Planells-Ferrer L, París-Coderch L, Tenbaum SP, Romero OA, Moubarak RS, Almazán-Moga A, Molist C, Roma J, Navarro S, Noguera R, Sánchez-Céspedes M, Comella JX, Palmer HG, Sánchez de Toledo J, Gallego S, Segura MF.

Oncogene. 2016 Sep 29;35(39):5179-90. doi: 10.1038/onc.2016.50. Epub 2016 Mar 21.

PMID:
26996667
22.

Genetic features of neuroblastic tumors associated with opsoclonus-myoclonus syndrome opens up the possibility for detection in peripheral blood.

Berbegall AP, López-Almaraz R, Navarro S, Noguera R.

Expert Rev Neurother. 2016 May;16(5):465-7. doi: 10.1586/14737175.2016.1163221. Epub 2016 Apr 6. No abstract available.

PMID:
26949993
23.

Vascular patterns provide therapeutic targets in aggressive neuroblastic tumors.

Tadeo I, Bueno G, Berbegall AP, Fernández-Carrobles MM, Castel V, García-Rojo M, Navarro S, Noguera R.

Oncotarget. 2016 Apr 12;7(15):19935-47. doi: 10.18632/oncotarget.7661.

24.

The genetic tumor background is an important determinant for heterogeneous MYCN-amplified neuroblastoma.

Bogen D, Brunner C, Walder D, Ziegler A, Abbasi R, Ladenstein RL, Noguera R, Martinsson T, Amann G, Schilling FH, Ussowicz M, Benesch M, Ambros PF, Ambros IM.

Int J Cancer. 2016 Jul 1;139(1):153-63. doi: 10.1002/ijc.30050. Epub 2016 Mar 22.

25.

Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma.

Decock A, Ongenaert M, Cannoodt R, Verniers K, De Wilde B, Laureys G, Van Roy N, Berbegall AP, Bienertova-Vasku J, Bown N, Clément N, Combaret V, Haber M, Hoyoux C, Murray J, Noguera R, Pierron G, Schleiermacher G, Schulte JH, Stallings RL, Tweddle DA; Children’s Cancer and Leukaemia Group (CCLG), De Preter K, Speleman F, Vandesompele J.

Oncotarget. 2016 Jan 12;7(2):1960-72. doi: 10.18632/oncotarget.6477.

26.

Comparative genetic study of intratumoral heterogenous MYCN amplified neuroblastoma versus aggressive genetic profile neuroblastic tumors.

Berbegall AP, Villamón E, Piqueras M, Tadeo I, Djos A, Ambros PF, Martinsson T, Ambros IM, Cañete A, Castel V, Navarro S, Noguera R.

Oncogene. 2016 Mar 17;35(11):1423-32. doi: 10.1038/onc.2015.200. Epub 2015 Jun 29.

PMID:
26119945
27.

Comparison of RNA-seq and microarray-based models for clinical endpoint prediction.

Zhang W, Yu Y, Hertwig F, Thierry-Mieg J, Zhang W, Thierry-Mieg D, Wang J, Furlanello C, Devanarayan V, Cheng J, Deng Y, Hero B, Hong H, Jia M, Li L, Lin SM, Nikolsky Y, Oberthuer A, Qing T, Su Z, Volland R, Wang C, Wang MD, Ai J, Albanese D, Asgharzadeh S, Avigad S, Bao W, Bessarabova M, Brilliant MH, Brors B, Chierici M, Chu TM, Zhang J, Grundy RG, He MM, Hebbring S, Kaufman HL, Lababidi S, Lancashire LJ, Li Y, Lu XX, Luo H, Ma X, Ning B, Noguera R, Peifer M, Phan JH, Roels F, Rosswog C, Shao S, Shen J, Theissen J, Tonini GP, Vandesompele J, Wu PY, Xiao W, Xu J, Xu W, Xuan J, Yang Y, Ye Z, Dong Z, Zhang KK, Yin Y, Zhao C, Zheng Y, Wolfinger RD, Shi T, Malkas LH, Berthold F, Wang J, Tong W, Shi L, Peng Z, Fischer M.

Genome Biol. 2015 Jun 25;16:133. doi: 10.1186/s13059-015-0694-1.

28.

Critical evaluation of three hemodynamic models for the numerical simulation of intra-stent flows.

Chabi F, Champmartin S, Sarraf C, Noguera R.

J Biomech. 2015 Jul 16;48(10):1769-76. doi: 10.1016/j.jbiomech.2015.05.011. Epub 2015 May 19.

PMID:
26044195
29.

Two independent epigenetic biomarkers predict survival in neuroblastoma.

Yáñez Y, Grau E, Rodríguez-Cortez VC, Hervás D, Vidal E, Noguera R, Hernández M, Segura V, Cañete A, Conesa A, Font de Mora J, Castel V.

Clin Epigenetics. 2015 Feb 27;7:16. doi: 10.1186/s13148-015-0054-8. eCollection 2015.

30.

Individual patient risk stratification of high-risk neuroblastomas using a two-gene score suited for clinical use.

von Stedingk K, De Preter K, Vandesompele J, Noguera R, Øra I, Koster J, Versteeg R, Påhlman S, Lindgren D, Axelson H.

Int J Cancer. 2015 Aug 15;137(4):868-77. doi: 10.1002/ijc.29461. Epub 2015 Feb 20.

31.

CASP8 SNP D302H (rs1045485) is associated with worse survival in MYCN-amplified neuroblastoma patients.

Rihani A, De Wilde B, Zeka F, Laureys G, Francotte N, Tonini GP, Coco S, Versteeg R, Noguera R, Schulte JH, Eggert A, Stallings RL, Speleman F, Vandesompele J, Van Maerken T.

PLoS One. 2014 Dec 11;9(12):e114696. doi: 10.1371/journal.pone.0114696. eCollection 2014.

32.

Anal tuberculosis complicating anti-TNFα therapy.

Luquín N, Masiá M, Noguera R, Gutiérrez F.

BMJ Case Rep. 2014 Nov 24;2014. pii: bcr2014206976. doi: 10.1136/bcr-2014-206976.

33.

Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification.

Defferrari R, Mazzocco K, Ambros IM, Ambros PF, Bedwell C, Beiske K, Bénard J, Berbegall AP, Bown N, Combaret V, Couturier J, Erminio G, Gambini C, Garaventa A, Gross N, Haupt R, Kohler J, Jeison M, Lunec J, Marques B, Martinsson T, Noguera R, Parodi S, Schleiermacher G, Tweddle DA, Valent A, Van Roy N, Vicha A, Villamon E, Tonini GP.

Br J Cancer. 2015 Jan 20;112(2):290-5. doi: 10.1038/bjc.2014.557. Epub 2014 Nov 4.

34.

Intragenic anaplastic lymphoma kinase (ALK) rearrangements: translocations as a novel mechanism of ALK activation in neuroblastoma tumors.

Fransson S, Hansson M, Ruuth K, Djos A, Berbegall A, Javanmardi N, Abrahamsson J, Palmer RH, Noguera R, Hallberg B, Kogner P, Martinsson T.

Genes Chromosomes Cancer. 2015 Feb;54(2):99-109. doi: 10.1002/gcc.22223. Epub 2014 Sep 23.

PMID:
25251827
35.

Revised risk estimation and treatment stratification of low- and intermediate-risk neuroblastoma patients by integrating clinical and molecular prognostic markers.

Oberthuer A, Juraeva D, Hero B, Volland R, Sterz C, Schmidt R, Faldum A, Kahlert Y, Engesser A, Asgharzadeh S, Seeger R, Ohira M, Nakagawara A, Scaruffi P, Tonini GP, Janoueix-Lerosey I, Delattre O, Schleiermacher G, Vandesompele J, Speleman F, Noguera R, Piqueras M, Bénard J, Valent A, Avigad S, Yaniv I, Grundy RG, Ortmann M, Shao C, Schwab M, Eils R, Simon T, Theissen J, Berthold F, Westermann F, Brors B, Fischer M.

Clin Cancer Res. 2015 Apr 15;21(8):1904-15. doi: 10.1158/1078-0432.CCR-14-0817. Epub 2014 Sep 17.

36.

Neuroblastoma patient-derived orthotopic xenografts retain metastatic patterns and geno- and phenotypes of patient tumours.

Braekeveldt N, Wigerup C, Gisselsson D, Mohlin S, Merselius M, Beckman S, Jonson T, Börjesson A, Backman T, Tadeo I, Berbegall AP, Ora I, Navarro S, Noguera R, Påhlman S, Bexell D.

Int J Cancer. 2015 Mar 1;136(5):E252-61. doi: 10.1002/ijc.29217. Epub 2014 Oct 7.

37.

Neuroblastoma after childhood: prognostic relevance of segmental chromosome aberrations, ATRX protein status, and immune cell infiltration.

Berbegall AP, Villamón E, Tadeo I, Martinsson T, Cañete A, Castel V, Navarro S, Noguera R.

Neoplasia. 2014 Jun;16(6):471-80. doi: 10.1016/j.neo.2014.05.012.

38.

Glycosaminoglycan profiling in different cell types using infrared spectroscopy and imaging.

Brézillon S, Untereiner V, Lovergne L, Tadeo I, Noguera R, Maquart FX, Wegrowski Y, Sockalingum GD.

Anal Bioanal Chem. 2014 Sep;406(24):5795-803. doi: 10.1007/s00216-014-7994-2. Epub 2014 Jul 15.

PMID:
25023968
39.

Biotensegrity of the extracellular matrix: physiology, dynamic mechanical balance, and implications in oncology and mechanotherapy.

Tadeo I, Berbegall AP, Escudero LM, Alvaro T, Noguera R.

Front Oncol. 2014 Mar 4;4:39. doi: 10.3389/fonc.2014.00039. eCollection 2014. Review.

40.

TMA vessel segmentation based on color and morphological features: application to angiogenesis research.

Fernández-Carrobles MM, Tadeo I, Bueno G, Noguera R, Déniz O, Salido J, García-Rojo M.

ScientificWorldJournal. 2013 Dec 5;2013:263190. doi: 10.1155/2013/263190. eCollection 2013.

41.

Lack of association between MDM2 promoter SNP309 and clinical outcome in patients with neuroblastoma.

Rihani A, Van Maerken T, De Wilde B, Zeka F, Laureys G, Norga K, Tonini GP, Coco S, Versteeg R, Noguera R, Schulte JH, Eggert A, Stallings RL, Speleman F, Vandesompele J.

Pediatr Blood Cancer. 2014 Oct;61(10):1867-70. doi: 10.1002/pbc.24927. Epub 2014 Jan 4.

PMID:
24391119
42.

Quantitative modeling of clinical, cellular, and extracellular matrix variables suggest prognostic indicators in cancer: a model in neuroblastoma.

Tadeo I, Piqueras M, Montaner D, Villamón E, Berbegall AP, Cañete A, Navarro S, Noguera R.

Pediatr Res. 2014 Feb;75(2):302-14. doi: 10.1038/pr.2013.217. Epub 2013 Nov 11.

PMID:
24216542
43.

snoRNPs Regulate Telomerase Activity in Neuroblastoma and Are Associated with Poor Prognosis.

von Stedingk K, Koster J, Piqueras M, Noguera R, Navarro S, Påhlman S, Versteeg R, Ora I, Gisselsson D, Lindgren D, Axelson H.

Transl Oncol. 2013 Aug 1;6(4):447-57. Print 2013 Aug.

44.

New prognostic markers in neuroblastoma.

Navarro S, Piqueras M, Villamón E, Yáñez Y, Balaguer J, Cañete A, Noguera R.

Expert Opin Med Diagn. 2012 Nov;6(6):555-67. doi: 10.1517/17530059.2012.704018. Epub 2012 Jul 11.

PMID:
23480837
45.

Genetic instability and intratumoral heterogeneity in neuroblastoma with MYCN amplification plus 11q deletion.

Villamón E, Berbegall AP, Piqueras M, Tadeo I, Castel V, Djos A, Martinsson T, Navarro S, Noguera R.

PLoS One. 2013;8(1):e53740. doi: 10.1371/journal.pone.0053740. Epub 2013 Jan 14.

46.

Focal DNA copy number changes in neuroblastoma target MYCN regulated genes.

Kumps C, Fieuw A, Mestdagh P, Menten B, Lefever S, Pattyn F, De Brouwer S, Sante T, Schulte JH, Schramm A, Van Roy N, Van Maerken T, Noguera R, Combaret V, Devalck C, Westermann F, Laureys G, Eggert A, Vandesompele J, De Preter K, Speleman F.

PLoS One. 2013;8(1):e52321. doi: 10.1371/journal.pone.0052321. Epub 2013 Jan 4.

47.

NeuPAT: an intranet database supporting translational research in neuroblastic tumors.

Villamón E, Piqueras M, Meseguer J, Blanquer I, Berbegall AP, Tadeo I, Hernández V, Navarro S, Noguera R.

Comput Biol Med. 2013 Mar;43(3):219-28. doi: 10.1016/j.compbiomed.2012.11.011. Epub 2013 Jan 4.

PMID:
23290604
48.

Exon-level expression analyses identify MYCN and NTRK1 as major determinants of alternative exon usage and robustly predict primary neuroblastoma outcome.

Schramm A, Schowe B, Fielitz K, Heilmann M, Martin M, Marschall T, Köster J, Vandesompele J, Vermeulen J, de Preter K, Koster J, Versteeg R, Noguera R, Speleman F, Rahmann S, Eggert A, Morik K, Schulte JH.

Br J Cancer. 2012 Oct 9;107(8):1409-17. doi: 10.1038/bjc.2012.391.

49.

Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkers.

Decock A, Ongenaert M, Hoebeeck J, De Preter K, Van Peer G, Van Criekinge W, Ladenstein R, Schulte JH, Noguera R, Stallings RL, Van Damme A, Laureys G, Vermeulen J, Van Maerken T, Speleman F, Vandesompele J.

Genome Biol. 2012 Oct 3;13(10):R95. doi: 10.1186/gb-2012-13-10-r95.

50.

Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project.

Schleiermacher G, Mosseri V, London WB, Maris JM, Brodeur GM, Attiyeh E, Haber M, Khan J, Nakagawara A, Speleman F, Noguera R, Tonini GP, Fischer M, Ambros I, Monclair T, Matthay KK, Ambros P, Cohn SL, Pearson AD.

Br J Cancer. 2012 Oct 9;107(8):1418-22. doi: 10.1038/bjc.2012.375. Epub 2012 Sep 13.

Supplemental Content

Loading ...
Support Center